Achi news desk-
Co-founded in 2012 by chief executive Adam Christie and chief technology officer Bruce Vernon, the company’s imaging system uses biological diagnostics to allow for preventative treatment before tooth decay becomes irreversible. Following its US launch, Calcivis is targeting a subsequent launch in the UK and other European markets.
READ MORE: Scottish dental pioneer Calcivis eyes US growth after FDA approval
“Early diagnosis and treatment of tooth decay is essential, enabling patients to reverse the damage to their teeth before it is too late,” said Mr Christie. “This investment will enable us to launch our innovative product into global markets – first in the US and eventually in the UK – leading to faster diagnosis and early intervention treatments.
“This technology has the potential to revolutionize prevention in oral health care, with cavities affecting more than two billion people worldwide, according to the World Health Organization. We look forward to seeing where this product can go with the support of the National Investment Bank of Scotland, and the Scottish Investment Fund, through Maven.”
Paul Callaghan, investment director at Scottish National Investment Bank, added: “Calcivis is a great example of how Scotland is leading the way in developing cutting-edge technology that improves our health and wellbeing. We are proud to help the company expand and enable its flagship product to reach international markets, creating jobs in Scotland.
“As a development investment bank, we see the Calcivis technology as fully aligned with our Innovation mission, and the UK launch of the product has the potential to deliver significant health benefits to people in Scotland.”
